A clinical constraint on lenalidomide-driven TH17 reprogramming

This pattern does not fit a simple exposure-only model.If lenalidomide-induced TH17 reprogramming contributes clinically, it is more likely an enabling condition than a sufficient cause, with host, treatment, or temporal factors gating the phenotype.The cases suggest and constrain candidate modifiers.Glucocorticoid context is one: six combination cycles passed without a flare, and the index flare followed dexamethasone cessation [4], whereas De Novellis et al. observed psoriasis during a dexamethasone-containing regimen [3].Withdrawal cannot explain all three cases.In cohort studies, lesion worsening followed steroid tapering or cessation in 114 of 703 instances, but no documented flare, intensive-care admission, or death was attributed to tapering or cessation; in case series, clinicians attributed 10.8% of psoriasis flares to systemic steroids (95% confidence interval, 4.6%-17.0%)[5].Clinical improvement is also confounded by phototherapy, which preceded marked improvement in all three cases [2-4]; De Novellis et al. attributed later freedom from flares to its local immunomodulatory effects [3].The IL-17 data suggest a reading not developed in the discussion.Lenalidomide increased total IL-17A and IL-17F in culture supernatants while decreasing the percentage of IL-17-expressing cells detected by intracellular flow cytometry.The authors reported a comparable discordance between intracellular staining and bulk measurements under IL-2 neutralization, which they attributed to feedback and secreted-cytokine signaling.The perturbation experiments may dissect it further: Ikaros knockout significantly reduced the frequency of IL-17A-expressing cells, Aiolos knockout did not significantly alter it, and Eos overexpression increased IL-17A-expressing cells and IL-17A/F output alongside other inflammatory cytokines while suppressing IL-10 [1].Because lenalidomide degrades Ikaros and Aiolos while raising Eos, one interpretation is that the fall in IL-17A-positive frequency reflects Ikaros loss, whereas increased secreted IL-17A reflects Eos gain.This decomposition remains inferential because the perturbations were not combined with lenalidomide and attempted IKZF4 knockout did not yield confirmed protein downregulation.